Vertex Pharmaceuticals (VRTX) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
259.9mn → 258.0mn diluted shares since FY21. Broadly flat, so EPS moves with net income rather than with the share count.
+47.0% YoY in FY25 · 3.6% of revenue.
$2.0B returned vs $3.2B of FCF in FY25. Buybacks covered by cash flow.
33¢ of every revenue dollar becomes profit. The biggest cost lever is operating expenses.
Over this window: gross 88.1% → 86.2%. Net margin 32.9% is more than double the sector median.
| Line item | TTM † | FY25 | FY24 | FY23 | FY22 | FY21 | YoY | CAGR 21→25 |
|---|---|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||||
Revenue | 12,951.6 | 12,001.3 | 11,020.1 | 9,869.2 | 8,930.7 | 7,574.4 | ▲8.9% | +12.2% |
Cost of revenue | 1,874.1 | 1,651.3 | 1,530.5 | 1,262.2 | 1,080.3 | 904.2 | ▲7.9% | +16.2% |
Gross profit | 11,077.5 | 10,350.0 | 9,489.6 | 8,607.0 | 7,850.4 | 6,670.2 | ▲9.1% | +11.6% |
Research & development | 4,368.7 | 4,042.5 | 8,258.7 | 3,690.0 | 2,655.8 | 3,051.1 | ▼51.1% | +7.3% |
Selling, general & admin | 2,407.0 | 1,753.1 | 1,464.3 | 1,136.6 | 944.7 | 840.1 | ▲19.7% | +20.2% |
Total operating expenses | 6,773.7 | 6,176.7 | 9,722.5 | 4,775.0 | 3,543.0 | 3,888.1 | ▼36.5% | +12.3% |
Operating incomefeeds ROC rank | 4,303.8 | 4,173.3 | −232.9 | 3,832.0 | 4,307.4 | 2,782.1 | — | +10.7% |
Other income, net | 455.3 | 469.9 | 481.4 | 547.8 | −75.0 | −51.7 | — | — |
Pretax income | 4,759.1 | 4,643.2 | 248.5 | 4,379.8 | 4,232.4 | 2,730.4 | ▲1768.5% | +14.2% |
Income tax | 783.2 | 690.0 | 784.1 | 760.2 | 910.4 | 388.3 | ▼12.0% | +15.5% |
Net incomePiotroski ROA ✓feeds Buffett Quality owner earnings | 3,975.9 | 3,953.2 | −535.6 | 3,619.6 | 3,322.0 | 2,342.1 | — | +14.0% |
| Per share | ||||||||
Diluted EPSbuyback-sensitive | 15.53 | 15.32 | −2.08 | 13.89 | 12.82 | 9.01 | — | +14.2% |
Diluted shares (mn) | 255.20 | 258.00 | 257.90 | 260.50 | 259.10 | 259.90 | ▲0.0% | −0.2% |
| Margins | ||||||||
Gross margin79th pct in Healthcare | 85.5% | 86.2% | 86.1% | 87.2% | 87.9% | 88.1% | ▲0.1pp | −1.8pp |
Operating margin | 33.2% | 34.8% | −2.1% | 38.8% | 48.2% | 36.7% | ▲36.9pp | −2.0pp |
Net margin95th pct in Healthcare | 30.7% | 32.9% | −4.9% | 36.7% | 37.2% | 30.9% | ▲37.8pp | +2.0pp |
Statements normalized in our fundamentals DB · Not investment advice.
Common questions
What was Vertex Pharmaceuticals' revenue last fiscal year?
Vertex Pharmaceuticals reported revenue of $12.0B in fiscal 2025, up 8.9% from fiscal 2024.
What was Vertex Pharmaceuticals' net income?
Vertex Pharmaceuticals reported net income of $4.0B in fiscal 2025, a net margin of 32.9%.

